Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the ...

Cash, cash equivalents and marketable securities were $352.4 million as of December 31, 2024, compared to $75.2 million as of December 31, ...

Metsera ,” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from f ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...

We expect 2025 to be another year of execution and growth, as we rapidly advance Metsera’s portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” Pipeline ...

We expect 2025 to be another year of execution and growth, as we rapidly advance Metsera's portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” MET-097i is a fully ...